Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250034/S004

Optune Pax

Novocure, GmbH · Decision date Oct 26, 2026

MEDTECHLEDGER EXPLANATIONP250034/S004

What did the FDA decide?

FDA recorded decision OK30 on 2026-10-26 for Optune Pax under PMA P250034, supplement S004, a 30-Day Notice filed under the reason "Process Change - Manufacturer/Sterilizer/Packager/Supplier." The stated purpose is "approval for changes to the sterilization load configuration." The source does not identify which sterilizer, facility, load size, cycle, or validated parameters changed, so the specific configuration change cannot be described beyond that label.

The P250034 identifier indicates this action amends the existing PMA rather than granting a new approval of the whole system. The record lists the device category as Low Electric Field Generator for Pancreatic Cancer Treatment with product code SHC; the supplement's stated purpose concerns sterilization load configuration, which is a manufacturing matter. That reported purpose is not independent proof of safety or clinical effectiveness, and no new indication should be inferred.

FDA approval order statement

approval for changes to the sterilization load configuration.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
General, Plastic Surgery
Decision date
Oct 26, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250034/S004
Regulatory pathway
PMA supplement
Product code
SHC
Decision code
OK30
Decision date
Oct 26, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Low Electric Field Generator for Pancreatic Cancer Treatment.

Product code
SHC
FDA device class
3

For the original device and its historical approval scope, see PMA P250034. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250034/S004 received

    Application receipt date recorded by FDA.

  2. P250034/S004 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P250034. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250034

Product / regulatory recordCompanyPathwayDecision dateSource
Optune PaxP250034
Novocure, GmbHPMA approvalFeb 11, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Novocure, GmbH

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Neuhofstrasse 21, Baar, 6340

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records